Incentivising the development of new antibacterial treatments 2024

Since 2021, G7 Finance and Health Ministers have reaffirmed their dedication to advancing AMR measures, tackling market failure and the antibiotic pipeline, maintaining access to necessary medicines, and improving research and research and development to commercialize novel antibacterials, especially for the susceptible groups most affected by AMR. The present study provides a yearly summary of the funding environment for antibacterial innovation, monitors national advancements, and lists important initiatives for the upcoming year to assist G7 policy objectives actions.